Media coverage
1
Media coverage
Title Fox Chase Cancer Center Details Findings in Carcinomas (Pembrolizumab Plus Axitinib Versus Sunitinib As First-line Treatment of Advanced Renal Cell Carcinoma: 43-month Follow-up of the Phase 3 Keynote-426 Study) Media name/outlet Immunotherapy Daily Country/Territory United States Date 11/29/23 Persons Elizabeth R. Plimack